Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTIS: Ranibizumab 1+PRN vs 3+PRN in Chinese wet AMD patients
NCT02810808Phase 4Unknown
- Sponsor
- Shanghai General Hospital
- Start
- Dec 2013
- Primary completion
- Sep 2016
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ranibizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Shanghai General Hospital. Status: unknown.
02
Drugs
ranibizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT02810808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02810808.